The regulation of Protein Phosphatase 4 by FBXO42 is required for cancer cell survival.
Stephan H. SpangenbergiD, Nicholas GaraffoiD, Enya Marie Catherine AlcindoriD, Benjamin L. Lusk, Vijaya PandeyiD, Adam D LonghurstiD, Emma BolechiD, Becky Xu Hua FuiD, Luke A. GilbertiD, James Akira WohlschlegeliD, David Paul ToczyskiiD
Abstract
FBXO42 is a poorly characterized F-box protein that is essential in 15% of cancer cell lines from diverse tissue types. FBXO42 has been implicated in the regulation of mitosis and p53 signaling. High-throughput approaches indicate that FBXO42 function correlates with that of CCDC6, and that the two proteins interact physically, but the relationship between these proteins is not understood. Through a genome-wide CRISPR knockout screen, we found that mutation of FBXO42 is synthetically lethal with mutations in the {gamma}- tubulin ring complex proteins MZT1 and MZT2B, suggesting that cells with centrosome and/or mitotic spindle assembly dysfunction are more sensitive to FBXO42 loss. Furthermore, we found that FBXO42 and CCDC6 contribute to p53 activation in response to centrosome depletion. Using mass spectrometry-based proteomics, we found that FBXO42 binds, is required for the ubiquitination of, and negatively regulates the expression of PPP4C (protein phosphatase 4 catalytic subunit). FBXO42s interaction with PPP4C was independent of CCDC6. Similarly, we found that CCDC6 physically interacts with PPP4C independently of FBXO42 and does not affect PPP4C ubiquitination. Knockdown of PPP4C reduced FBXO42-CCDC6 interactions, suggesting that FBXO42 and CCDC6 may bind to and regulate PPP4C through separate mechanisms. Using gene knockdown rescue experiments, we confirmed that aberrant expression of PPP4C is a major driver of cell death in an FBXO42-essential Neuroblastoma cell line. These findings shed light on the function of two poorly understood proteins in regulating PP4 activity, p53 signaling, mitosis and cancer cell survival. A better understanding of FBXO42 and CCDC6 could inform the development of targeted cancer therapeutics.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 3
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Pervasive phenotypic effects of Fbxo42 controlled by regulation of PP4 phosphatase
Hongbin Yang, Paul Smith, … Vincenzo D’Angiolella·bioRxiv·May 2, 2025
- FBXO42 activity is required to prevent mitotic arrest, spindle assembly checkpoint activation, and lethality in glioblastoma and other cancers
P. Hoellerbauer, M. Kufeld, … P. PADDISON·bioRxiv·Nov 29, 2022
- FBXO45-MYCBP2 regulates mitotic cell fate by targeting FBXW7 for degradation
I. Hoffmann, K. T. Richter, … B. Vodicska·bioRxiv·Mar 20, 2019
- The RASSF6 tumor suppressor protein regulates apoptosis and cell cycle progression via Retinoblastoma protein.
Shakhawoat Hossain, Hiroaki Iwasa, … Yutaka Hata·Molecular and Cellular BiologyPeer-reviewed·Jun 12, 2018
- PIP4K2B is a mechanosensor and induces heterochromatin-driven nuclear softening through UHRF1.
A. Poli, F. A. Pennacchio, … P. Maiuri·bioRxiv·Mar 25, 2022
- FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis
S. P. Turunen, P. von Nandelstadh, … K. Lehti·bioRxiv·Oct 2, 2018